M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

Phase 4

Completed

Conditions: Cutaneous T Cell Lymphoma
Mycosis Fungoides

Interventions: Drug: Methoxsalen+ECP

First Posted Date: 2005-09-22

Last Posted Date: 2018-08-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00221039

Locations: 🇺🇸
Rush-Presbyterian Hospital, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 4 locations

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

Not Applicable

Terminated

Conditions: Bladder Cancer
Genitourinary Cancer
Prostate Cancer

Interventions: Drug: Ferumoxtran-10 (USPIO)
Procedure: MR lymphangiography

First Posted Date: 2005-09-07

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00147238

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

Phase 1

Completed

Conditions: Solid Tumors
Advanced Cancer

Interventions: Drug: AMG 531
Drug: Carboplatin
Drug: Adriamycin
Drug: Ifosfamide

First Posted Date: 2005-09-07

Last Posted Date: 2014-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00147225

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

Conditions: Leukemia, Myelogenous, Chronic

Interventions: Drug: Nilotinib

First Posted Date: 2005-08-12

Last Posted Date: 2019-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 148

Registration Number: NCT00129740

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

Phase 2

Withdrawn

Conditions: Hodgkin's Disease
Lymphoma

Interventions: Drug: Alemtuzumab (Campath-1H)

First Posted Date: 2005-08-12

Last Posted Date: 2018-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00129753

Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma

Not Applicable

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Curcumin
Drug: Bioperine

First Posted Date: 2005-06-13

Last Posted Date: 2011-11-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00113841

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma
Islet Cell Carcinoma

Interventions: Drug: RAD001
Drug: Octreotide Depot

First Posted Date: 2005-06-08

Last Posted Date: 2023-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 67

Registration Number: NCT00113360

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2005-06-08

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00113321

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Erlotinib
Drug: Docetaxel
Radiation: Radiation Therapy

First Posted Date: 2005-06-08

Last Posted Date: 2012-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00113347

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: ABT-510

First Posted Date: 2005-06-08

Last Posted Date: 2014-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00113334

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy